SCHEMBL12435451

SCHEMBL12435451

O=C(Nc1cc(Cl)cc(C(F)(F)F)c1)Oc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC13A3 Q8WWT9 1/20 0.52
P2RX1 P51575 5/20 0.50
P2RX4 Q99571 1/20 0.50
P2RX7 Q99572 1/20 0.50
TMPRSS4 Q9NRS4 1/20 0.49
TRPV1 Q8NER1 1/20 0.45
MAPT P10636 4/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 3/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
KIF11 P52732 1/20 0.43
ATM Q13315 1/20 0.43
MGLL Q99685 1/20 0.42
POLB P06746 1/20 0.42
MAPK1 P28482 1/20 0.41
MYOC Q99972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12435446 0.92 P2RX1 (0.57) P2RX1P2RX4P2RX7TMPRSS4MAPT
SCHEMBL12586249 0.86 P2RX1 (0.49) P2RX1P2RX4P2RX7TMPRSS4MAPT
SCHEMBL12435452 0.86 P2RX1 (0.49) P2RX1P2RX4P2RX7TMPRSS4MAPT
SCHEMBL8533351 0.83 MAPT (0.64) TRPV1MAPTMEN1KMT2ALMNA
SCHEMBL1077965 0.83 SLC13A3 (0.59) SLC13A3P2RX1TRPV1MAPTMEN1
SCHEMBL10308069 0.83 ABCG2 (0.54) TRPV1MAPTMEN1KMT2AGAA
SCHEMBL10308063 0.79 MAPT (0.47) TRPV1MAPTMEN1KMT2ALMNA
SCHEMBL27892246 0.79 KDR (0.54) MAPTMEN1KMT2ALMNAGAA
SCHEMBL2082944 0.79 KMT2A (0.58) MAPTMEN1KMT2ALMNAGAA
SCHEMBL31308883 0.77 MAPT (0.57) MAPTMEN1KMT2ALMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE49686-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-10 US disclosed
US-RE48334-E1 Nitrogen-containing heterocyclic compound and use of same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-12-01 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-07-21 US disclosed
EP-2336105-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME Takeda Pharmaceutical Company Limited (JP) 2011-06-22 EP disclosed
WO-2010032856-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME 武田薬品工業株式会社 (JP) 2010-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178060-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME NTSR2, BDKRB1, AVPR1B SLC13A3 488/4885P2RX1 1137/4885P2RX4 1210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.